Raymond James Financial
SAGE

Raymond James Financial’s Sage Therapeutics SAGE Stock Holding History

Raymond James Financial’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,054
Closed -$9.61K – 6420
2025
Q2 		$9.61K Buy
+1,054
New +$7.75K ﹤0.01% 5934

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Raymond James Financial's SAGE Position: Q3 2025 in Review

Raymond James Financial sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,054 shares — an estimated $9.61K sold.

Raymond James Financial first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $9.61K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Raymond James Financial reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,054 Sage Therapeutics shares in Q3 2025, an estimated $9.61K.
  • Raymond James Financial first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Sage Therapeutics position peaked at $9.61K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.